Find a Clinical Trial

Showing 161 - 170 of 182 Trials

Phase 1 study of venetoclax/azacitidine or venetoclax in combination with ziftomenib (KO-539) or standard induction cytarabine/daunorubicin (7+3) chemotherapy in combination with ziftomenib for the treatment of patients with acute myeloid leukemia

Principal Investigator:

Joseph G. Jurcic, MD

Contact Number:

212-342-5162

NCT Number:

NCT05735184

Population:

Adult

Phase:

I

The purpose of this study is to determine the safe dose of ziftomenib to be used in combination with other drugs to treat acute myeloid leukemia. Another purpose is to determine how well ziftomenib works in combination with the other drugs for acute myeloid leukemia. Ziftomenib has not been approved by Food and Drug Administration (FDA). Ziftomenib is an experimental drug may help in preventing or slowing the leukemia cells from growing and dividing. Are you Eligible? (Inclusion Criteria) Must be 18 years old or older - Must have life expectancy greater than 3 months - Must not be diagnosis...
Phase I Study of Adoptive Immunotherapy of Refractory Viral Infection with ex vivo Expanded Rapidly Generated Virus Specific T (R-MVST) Cells

Principal Investigator:

Pawel Muranski, MD

Contact Number:

212-342-5162

NCT Number:

NCT05183490

Population:

Adult

Phase:

I

The purpose of this study is to test whether giving an experimental cell product can treat viral infection in patients who have conditions that cause the poor function of their immune system. The patients with infections caused by viruses such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), adenovirus (ADV), BK and JC polyomaviruses (PyVs) virus may participate in this study. The cell product is called rapidly generated virus-specific T cells (R-MVST). R-MVST cells will be manufactured in our laboratory at Columbia University Irving Medical Center. This cell product has not been approved...
Phase 1, Dose-Escalation Study of KTX-2001 (an NSD2 Inhibitor)Alone and in Combination with Darolutamide for MetastaticCastration-Resistant Prostate Cancer

Principal Investigator:

Alexander Z. Wei, MD

Contact Number:

212-342-5162

NCT Number:

NCT07103018

Population:

Adult

Phase:

I

KTX-2001 is effective for the treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC). The study drug KTX-2001 has been tested in animals but not yet in people, and it is experimental, which means it is not approved by the United States Food and Drug Administration (FDA). The study drug KTX-2001 is similar to another drug, KTX-1001, that has been tested in people with multiple myeloma, a blood cancer, except for a small change in its chemical makeup which may improve the features of the drug. Darolutamide is a drug that is FDA approved for people with non-metastatic castration-...
Phase 1, open label single-arm two-part study to investigate safety, pharmacokinetics, andpreliminary efficacy of pan-RAF/MEK glue NST-628 oral tablets in subjects with solid tumorsharboring genetic alterations in the MAPK pathway and with other solid

Principal Investigator:

Benjamin Herzberg, MD

Contact Number:

212-342-5162

NCT Number:

NCT06326411

Population:

Adult

Phase:

I

The purpose of this study is to find out if, and at what dose, NST-628 can safely treat solid cancers in patients who have no other treatment options left. NST-628 has been tested in animals and demonstrated some anti-tumor activity. This research study will be the first in which it will be given to humans and is experimental. “Experimental” means that the study drug has not been approved by any government authority responsible for the regulation of new medicines. This trial will explore what doses of NST-628 are safe and tolerable, as well as see whether NST-628 can slow the...
Phase 1/Expansion Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma

Principal Investigator:

Jennifer Effie Amengual, MD

Contact Number:

212-342-5162

NCT Number:

NCT05627245

Population:

Adult

Phase:

I

The purpose of this study is to test the safety of drugs called tazemetostat and belinostat when administered together. This study tests different doses of the drugs to see which doses are safer for people. There will be between 21 and 48 people taking part in this study. There are two parts in this study, a dose escalation (dose finding) part and a dose expansion part (where the established dose is tested further). In the dose escalation part of this study, different people will get different doses of the study drugs tazemetostat and belinostat. The first 3 people taking part in this study...
R5458-ONC-2012:PHASE 1B STUDY OF REGN5458 (ANTI-BCMA X ANTICD3 BISPECIFIC ANTIBODY) PLUS OTHER CANCER TREATMENTS FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Principal Investigator:

Rajshekhar Chakraborty, MD

Contact Number:

212-342-5162

NCT Number:

NCT05137054

Population:

Adult

Phase:

I

This study is the first time REGN5458 will be combined with other cancer therapies. The main goal is to understand if REGN5458 can be given safely with other cancer study treatments, and if so, what dose of REGN5458 should be used for each combination. The investigational drug, REGN5458, is not approved by the Food and Drug Administration (FDA). Are you Eligible? (Inclusion Criteria) Are you at least 18 years of age? - Are you likely to live for at least six more months? -Do you have measurable disease as defined in the protocol according to International Myeloma Working Group (IMWG)...
Safety and Efficacy of Brodalumab in the Treatment of Immune-Related Adverse Events: A PilotStudy

Principal Investigator:

Brian Henick, MD

Contact Number:

212-342-5162

NCT Number:

NCT06673329

Population:

Adult

Phase:

I

The purpose of this study is to test the safety and effectiveness of using brodalumab in patients who develop side effects from cancer immune therapy. Immune-related side effects are due to activation of the immune system in patients who previously received immunotherapy and the goal of this study is to help better control these side effects. Brodalumab is often used to treat patients with autoimmune diseases (diseases where the immune system is activated against normal organs) and safe doses and treatment schedules have been determined in these patients. Immune-related side effects appear to...
A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, + Best SupportiveCare Versus Best Supportive Care for Metastatic Castration-resistant Prostate Cancer

Principal Investigator:

Mark N. Stein, MD

Contact Number:

212-342-5162

NCT Number:

NCT07164443

Population:

Adult

Phase:

NA

The purpose of this study is to understand if a treatment (pasritamig) added to best supportive care (including radiation, steroids, pain medication, or medications to strengthen your bones) for metastatic castration-resistant prostate cancer (a form of advanced prostate cancer that has spread to other parts of the body) will work better than the best supportive care alone. The investigational study treatment is called pasritamig. Pasritamig is not approved by U.S. Food and Drug Administration (FDA) who are responsible to approve medications. Therefore, it can only be used in a research study...
A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE849 in Patients with DLL3 Expressing Tumors Including Small Cell Lung Cancer

Principal Investigator:

Benjamin Herzberg, MD

Contact Number:

212-342-5162

NCT Number:

NCT07174583

Population:

Adult

Phase:

NA

This is a research study that includes studying IDE849 in small cell lung cancer (SCLC) that has progressed or recurred (returned) after previous standard treatment. The purpose of this study is to determine the highest dose of IDE849 that can be safely given to participants. The study drug used in this study is called IDE849. The study drug will be given through an intravenous (IV - into the vein) infusion on a slow drip. Study drug will be given once every 3 weeks in 21-day cycles. IDE849 is an experimental drug that is not approved by the Food and Drug Administration (FDA). This research...
A Pragmatic Randomized Controlled Trial to Evaluate the Effectiveness of an Intervention called Current Together After Cancer (CTAC) to Promote Guideline-Concordant Colorectal Cancer Surveillance

Principal Investigator:

Yoanna S Pumpalova, MD

Contact Number:

212-342-5162

NCT Number:

NCT07018869

Population:

Adult

Phase:

NA

The purpose of this study is to see if using an educational website, called Current Together After Cancer (CTAC), can help people learn about follow-up care after colorectal cancer treatment. We want to see if the educational website will help people: • Understand the risk of colorectal cancer coming back • Understand the risk of developing a new cancer • Know what tests are important for looking for signs of cancer • Have an active role in monitoring their own health after treatment Are you Eligible? (Inclusion Criteria) Are you 18 years of age or older? Have you been...

Find a Clinical Trial

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Pages